PCR 2017

Booth M33 – Hall Maillot, Level 2.
“Interim data from an ongoing study show: pressure-controlled intermittent coronary sinus occlusion results in cardioprotection when given adjunct to PCI”
  1. Jain, Barts Heart Centre, London, UK
  • Abstract Euro17A-OP1053, presented during: Novel approaches for treatment of STEMI – Session comprising selected EuroPCR 2017 abstract submissions
  • TUESDAY, MAY 16, 2017, 3.30 PM, Room 252 A (Level 2)
Symposium sponsored by Miracor
TUESDAY, MAY 16, 2017, 5.15 PM – 6.45 PM, Room 241 (Level 2)
Targeting infarct size reduction to prevent heart failure”
Chairpersons: G.W. Stone, Columbia University, New York, USA
A. Zaman, Freeman Hospital, Newcastle, UK

JIM 2017

Endotech spa è presente al  JIM 2017 (Milano 9/11 Febbraio 2017)

Vi aspettiamo al nostro stand: #10

Previste le seguenti presentazioni:

9/2/17 presso ROOM PORTA (Lunch Symposia)


h. 13.45 Presentazione del PROF. SIEVERT: “Clinical experience with LAmbre LAA  Closure System”

10/2/17 presso ROOM CLUB (Lunch Symposia)


h. 13.15 Presentazione del DR. GIANNINI: “The coronary sinus Reducer. A device-based therapy for refractory angina.


The coronary sinus reducer: clinical evidence and technical aspects

Francesco GianniniAndrea AurelioRichard J. JabbourLuca FerriAntonio Colombo & Azeem Latib

Pages 47-58 | Received 26 Sep 2016, Accepted 07 Dec 2016, Accepted author version posted online: 09 Dec 2016, Published online: 15 Dec 2016


Introduction: Chronic refractory angina is often a disabling condition, predominantly due to severe obstructive coronary artery disease, that is inadequately controlled by optimal medical therapy and not amenable to further percutaneous or surgical revascularization. mortality rates associated with this condition are relatively low in clinically stable patients. however, it is associated with a high hospitalization rate and a reduction in both exercise capacity and quality of life. due to the paucity of available treatment options, there is an unmet need for new therapies for these patients and for a reduction in the associated economic healthcare burden.

Areas covered: This review is focusing on the clinical evidence and technical aspects of this new therapeutic modality in refractory angina patients unsuitable for revascularization.

Expert commentary: The Coronary Sinus Reducer (Neovasc Inc. Richmond B.C., Canada) is a new percutaneous device designed to achieve a controlled narrowing of the coronary sinus that may alleviate myocardial ischemia, possibly by redistributing blood from the less ischemic sub-epicardium to the more ischemic sub-endocardium, or by neoangiogenesis. Recently, a randomized, double-blind, multi-center clinical trial demonstrated a benefit in improving symptoms in 104 refractory angina patients, when compared to placebo.

KEYWORDS: Coronary sinus reducer implantationrefractory anginacoronary artery diseaseangina pectorismyocardial ischemia

Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study

RELEASE 28/11/2016 

Neovasc Inc. today announced it has received both regulatory and ethics committee approval to initiate the Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA II) in Italy.   TIARA II is a 115 patient, non-randomized, prospective clinical study evaluating the safety and performance of the Tiara™ Transcatheter Mitral Valve with the Tiara™ Transapical Delivery System (Tiara™).

With these critical approvals now in place, it is expected that the first Italian TIARA II clinical study site will be initiated before year end, with first enrollment anticipated early in the new year.  Approvals in additional geographies are expected in the first quarter of 2017.

TCT 2016 (29 Ottobre – 2 novembre 2016) Walter E. Washington Convention Center WASHINGTON, DC


Il 31/10, il Dr. Anson Cheung (St. Paul’s hospital, Vancouver) ha presentato un aggiornamento riguardo l’attuale programma inerente al valvola Mitrale TIARA™. Ha presentato i dati clinici ad oggi. 19 pazienti trattati. Tasso di sopravvivenza a 30g è dell’84%. Complessivamente i dati presentati sono incoraggianti.

Gli arruolamenti continuano per lo studio TIARA-I Early Feasibility ed in altri programmi ad uso compassionevole.

Lo studio TIARA-I ha lo scopo di valutare la sicurezza e  le performance della valvola mitrale TIARA oltre alla procedura di impianto in pazienti ad alto rischio che soffrono di rigurgito mitralico severo.

Il Dr. Florian Deuschl (Amburgo, Germania), ha esposto una presentazione intitolata “Echocardiographic Guiding of a Novel Mitral Valve Replacement” che riesamina la sua esperienza inerente l’impianto della valvola mitrale TIARA™.

Riguardo il prodotto REDUCER™ per il trattamento dell’angina refrattaria, il Dr. Gregg Stone ha presentato il REDUCER™ come l’opzione di trattamento più efficace per il trattamento dei pazienti che soffrono di angina refrattaria rispetto alla terapia medica.

Egli ha analizzato I risultati dello studio randomizzato COSIRA che è stato pubblicato sul  New England Journal of Medicine l’anno scorso.

Egli ha anche accennato allo studio, COSIRA II, (pivotal US trial) che includerà 380 pazienti, multicentrico, prospettivo,randomizzato, double-blind, sham-controlled.

Sono stati anche presentati 2 posters presentati dall’Italia che descrivono l’efficacia del sistema REDUCER

1 2 3 4